Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients

被引：41

作者：

Arnold, Danielle E. ^{[1
]}

Maude, Shannon L. ^{[2
,3
]}

Callahan, Colleen A. ^{[2
]}

DiNofia, Amanda M. ^{[2
,3
]}

Grupp, Stephan A. ^{[2
,3
]}

Heimall, Jennifer R. ^{[1
,3
]}

机构：

[1] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA

[2] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[3] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 03期

关键词：

B-cell aplasia; chimeric antigen receptor T cell; hypogammaglobulinemia; immunoglobulin replacement; subcutaneous immunoglobulin; REMISSIONS;

D O I：

10.1002/pbc.28092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-eight patients were maintained on subcutaneous immunoglobulin replacement for persistent B-cell aplasia and agammaglobulinemia following CD19-targeted chimeric antigen receptor T-cell therapy for B-cell lymphoblastic leukemia. Patients were transitioned from intravenous to subcutaneous immunoglobulin replacement at a median of 11.5 months (range, 4-20). Increasing serum IgG level was significantly associated with a lower rate of sinopulmonary infection (P = 0.0072). The median serum IgG level during infection-free periods was 1000 mg/dL (range, 720-1430), which was significantly higher than IgG levels in patients with sinopulmonary infections. As such, we recommend maintaining a goal IgG level > 1000 mg/dL to provide optimal protection.

引用

页数：4

共 13 条

[1] Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies [J].

Berger, Melvin ;

Rojavin, Mikhail ;

Kiessling, Peter ;

Zenker, Othmar .

CLINICAL IMMUNOLOGY, 2011, 139 (02) :133-141

[2] Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G [J].

Berger, Melvin ;

Murphy, Elyse ;

Riley, Patty ;

Bergman, Garrett E. .

SOUTHERN MEDICAL JOURNAL, 2010, 103 (09) :856-863

[3] Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis [J].

Fu, Lisa W. ;

Song, Christine ;

Isaranuwatchai, Wanrudee ;

Betschel, Stephen .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 120 (02) :195-199

[4] B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J].

Kochenderfer, James N. ;

Dudley, Mark E. ;

Feldman, Steven A. ;

Wilson, Wyndham H. ;

Spaner, David E. ;

Maric, Irina ;

Stetler-Stevenson, Maryalice ;

Phan, Giao Q. ;

Hughes, Marybeth S. ;

Sherry, Richard M. ;

Yang, James C. ;

Kammula, Udai S. ;

Devillier, Laura ;

Carpenter, Robert ;

Nathan, Debbie-Ann N. ;

Morgan, Richard A. ;

Laurencot, Carolyn ;

Rosenberg, Steven A. .

BLOOD, 2012, 119 (12) :2709-2720

[5] Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [J].

Kochenderfer, James N. ;

Wilson, Wyndham H. ;

Janik, John E. ;

Dudley, Mark E. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Maric, Irina ;

Raffeld, Mark ;

Nathan, Debbie-Ann N. ;

Lanier, Brock J. ;

Morgan, Richard A. ;

Rosenberg, Steven A. .

BLOOD, 2010, 116 (20) :4099-4102

[6] Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies [J].

Mallick, Rajiv ;

Jolles, Stephen ;

Kanegane, Hirokazu ;

Agbor-Tarh, Dominique ;

Rojavin, Mikhail .

JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (08) :886-897

[7] Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia [J].

Maude, S. L. ;

Laetsch, T. W. ;

Buechner, J. ;

Rives, S. ;

Boyer, M. ;

Bittencourt, H. ;

Bader, P. ;

Verneris, M. R. ;

Stefanski, H. E. ;

Myers, G. D. ;

Qayed, M. ;

De Moerloose, B. ;

Hiramatsu, H. ;

Schlis, K. ;

Davis, K. L. ;

Martin, P. L. ;

Nemecek, E. R. ;

Yanik, G. A. ;

Peters, C. ;

Baruchel, A. ;

Boissel, N. ;

Mechinaud, F. ;

Balduzzi, A. ;

Krueger, J. ;

June, C. H. ;

Levine, B. L. ;

Wood, P. ;

Taran, T. ;

Leung, M. ;

Mueller, K. T. ;

Zhang, Y. ;

Sen, K. ;

Lebwohl, D. ;

Pulsipher, M. A. ;

Grupp, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :439-448

[8] Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia [J].

Maude, Shannon L. ;

Frey, Noelle ;

Shaw, Pamela A. ;

Aplenc, Richard ;

Barrett, David M. ;

Bunin, Nancy J. ;

Chew, Anne ;

Gonzalez, Vanessa E. ;

Zheng, Zhaohui ;

Lacey, Simon F. ;

Mahnke, Yolanda D. ;

Melenhorst, Jan J. ;

Rheingold, Susan R. ;

Shen, Angela ;

Teachey, David T. ;

Levine, Bruce L. ;

June, Carl H. ;

Porter, David L. ;

Grupp, Stephan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) :1507-1517

[9] Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy [J].

Orange, J. S. ;

Belohradsky, B. H. ;

Berger, M. ;

Borte, M. ;

Hagan, J. ;

Jolles, S. ;

Wasserman, R. L. ;

Baggish, J. S. ;

Saunders, R. ;

Grimbacher, B. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 169 (02) :172-181

[10] Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies [J].

Orange, Jordan S. ;

Grossman, William J. ;

Navickis, Roberta J. ;

Wilkes, Mahlon M. .

CLINICAL IMMUNOLOGY, 2010, 137 (01) :21-30

← 1 2 →